Active surveillance of acute paediatric hospitalisations demonstrates the impact of vaccination programmes and informs vaccine policy in Canada and Australia.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
06 2020
Historique:
entrez: 3 7 2020
pubmed: 3 7 2020
medline: 9 7 2020
Statut: ppublish

Résumé

Sentinel surveillance of acute hospitalisations in response to infectious disease emergencies such as the 2009 influenza A(H1N1)pdm09 pandemic is well described, but recognition of its potential to supplement routine public health surveillance and provide scalability for emergency responses has been limited. We summarise the achievements of two national paediatric hospital surveillance networks relevant to vaccine programmes and emerging infectious diseases in Canada (Canadian Immunization Monitoring Program Active; IMPACT from 1991) and Australia (Paediatric Active Enhanced Disease Surveillance; PAEDS from 2007) and discuss opportunities and challenges in applying their model to other contexts. Both networks were established to enhance capacity to measure vaccine preventable disease burden, vaccine programme impact, and safety, with their scope occasionally being increased with emerging infectious diseases' surveillance. Their active surveillance has increased data accuracy and utility for syndromic conditions (e.g. encephalitis), pathogen-specific diseases (e.g. pertussis, rotavirus, influenza), and adverse events following immunisation (e.g. febrile seizure), enabled correlation of biological specimens with clinical context and supported responses to emerging infections (e.g. pandemic influenza, parechovirus, COVID-19). The demonstrated long-term value of continuous, rather than incident-related, operation of these networks in strengthening routine surveillance, bridging research gaps, and providing scalable public health response, supports their applicability to other countries.

Identifiants

pubmed: 32613939
doi: 10.2807/1560-7917.ES.2020.25.25.1900562
pmc: PMC7331140
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Euro Surveill. 2017 Feb 16;22(7):
pubmed: 28230524
Pediatrics. 2016 Feb;137(2):e20152848
pubmed: 26791970
Clin Infect Dis. 1999 Jun;28(6):1238-43
pubmed: 10451159
Pediatr Infect Dis J. 2010 Sep;29(9):879-82
pubmed: 20467353
Lancet Infect Dis. 2017 Jan;17(1):86-97
pubmed: 27789179
N Engl J Med. 2018 Apr 19;378(16):1521-1528
pubmed: 29669224
Emerg Infect Dis. 2011 Oct;17(10):1960-2
pubmed: 22000384
Pediatr Infect Dis J. 2007 Jan;26(1):31-5
pubmed: 17195702
Epidemiol Infect. 2016 Jul;144(10):2117-27
pubmed: 26916674
Neurology. 2012 Oct 2;79(14):1474-81
pubmed: 22993280
Vaccine. 2013 Dec 17;32(1):124-30
pubmed: 23588089
Vaccine. 2013 Sep 13;31(40):4448-58
pubmed: 23770307
Clin Infect Dis. 2014 Nov 1;59(9):1208-15
pubmed: 25069868
Commun Dis Intell Q Rep. 2017 Dec 1;41(4):E337-E347
pubmed: 29864387
Pediatrics. 2019 May;143(5):
pubmed: 31004046
Pediatr Infect Dis J. 2017 Jan;36(1):31-35
pubmed: 27749656
Commun Dis Intell Q Rep. 2013 Jun 30;37(2):E149-55
pubmed: 24168089
Can Commun Dis Rep. 1998 May 1;24(9):69-72; discussion 73-5
pubmed: 9611413
J Infect Dis. 2019 Jan 9;219(3):391-399
pubmed: 30184182
Clin Infect Dis. 2017 Aug 15;65(4):653-660
pubmed: 29017268
Pediatr Infect Dis J. 2018 Jul;37(7):726-728
pubmed: 29200182
Vaccine. 2018 Dec 14;36(51):7790-7793
pubmed: 29784471
Vaccine. 2018 Aug 6;36(32 Pt B):4939-4943
pubmed: 30037484
Pediatr Infect Dis J. 2000 Nov;19(11):1053-9
pubmed: 11099085
Commun Dis Intell (2018). 2019 Feb 01;43:
pubmed: 30727704
Med J Aust. 2019 Jun;210(11):484-486.e1
pubmed: 31063595
Pediatr Infect Dis J. 2003 Feb;22(2):119-22
pubmed: 12586974
Vaccine. 2010 Apr 19;28(18):3180-4
pubmed: 20189488
Pediatr Infect Dis J. 2005 Jun;24(6):538-41
pubmed: 15933565
Pediatrics. 2016 Sep;138(3):
pubmed: 27535144
Ann Intern Med. 2019 Apr 16;170(8):513-520
pubmed: 30831578
CMAJ. 1996 Apr 1;154(7):1041-7
pubmed: 8625025
JAMA Pediatr. 2017 Oct 1;171(10):992-998
pubmed: 28806450
JAMA. 2020 Jun 8;:
pubmed: 32511692
Clin Infect Dis. 2020 Jan 19;:
pubmed: 31955204
Pediatr Infect Dis J. 2010 Jun;29(6):559-61
pubmed: 20160658
Vaccine. 2010 Feb 25;28(9):2130-6
pubmed: 20044050
Clin Infect Dis. 2019 Mar 5;68(6):940-948
pubmed: 30137244
Pediatrics. 2003 Nov;112(5):e348
pubmed: 14595075
Vaccine. 2011 Apr 5;29(16):3061-6
pubmed: 21316503
Clin Infect Dis. 2017 Jun 1;64(11):1564-1572
pubmed: 28329167
Can Commun Dis Rep. 2018 Sep 06;44(9):206-214
pubmed: 31015811
Pediatr Infect Dis J. 2007 Nov;26(11):1025-31
pubmed: 17984810
Epidemiol Infect. 2017 May;145(7):1451-1460
pubmed: 28162130
PLoS Med. 2016 May 19;13(5):e1002042
pubmed: 27195954
Pediatr Infect Dis J. 2013 May;32(5):530-7
pubmed: 23249914
Euro Surveill. 2010 Dec 09;15(49):
pubmed: 21163183
Wkly Epidemiol Rec. 2014 Dec 5;89(49):545-50
pubmed: 25485342
Pediatr Infect Dis J. 2020 May;39(5):379-384
pubmed: 32091492
Clin Infect Dis. 2013 Nov;57(10):1427-34
pubmed: 23964090
Pediatrics. 2012 Sep;130(3):397-406
pubmed: 22931901
Semin Pediatr Infect Dis. 2003 Jul;14(3):213-9
pubmed: 12913834
Influenza Other Respir Viruses. 2019 Oct 31;:
pubmed: 31670892
Vaccine. 2015 Mar 10;33(11):1412-7
pubmed: 25444797
Pediatr Infect Dis J. 2014 Jul;33(7):710-4
pubmed: 24918745
Pediatr Infect Dis J. 2012 Sep;31(9):956-63
pubmed: 22647896
Vaccine. 2018 Jan 8;36(3):363-370
pubmed: 28803714
J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):118-127
pubmed: 30535079
Influenza Other Respir Viruses. 2014 Nov;8(6):636-45
pubmed: 25263176
J Infect. 2019 Mar;78(3):220-225
pubmed: 30528868
Euro Surveill. 2016 Jul 28;21(30):
pubmed: 27494798

Auteurs

Karina A Top (KA)

Department of Pediatrics, Dalhousie University, Halifax, Canada.
Canadian Center for Vaccinology, IWK Health Centre, Halifax, Canada.
These authors contributed equally.

Kristine Macartney (K)

These authors contributed equally.
National Centre for Immunisation Research and Surveillance and The Children's Hospital Westmead, Sydney, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

Julie A Bettinger (JA)

University of British Columbia and Vaccine Evaluation Center, British Columbia Children's Hospital, Vancouver, Canada.

Ben Tan (B)

University of Saskatchewan, Royal University Hospital, Saskatoon, Canada.

Christopher C Blyth (CC)

Telethon Kids Institute and School of Medicine, University of Western Australia and Perth Children's Hospital, Perth, Australia.

Helen S Marshall (HS)

Robinson Research Institute and Adelaide Medical School, The University of Adelaide and VIRTU Women's and Children's Health Network, Adelaide, Australia.

Wendy Vaudry (W)

University of Alberta, Stollery Children's Hospital, Edmonton, Canada.

Scott A Halperin (SA)

Department of Pediatrics, Dalhousie University, Halifax, Canada.
Canadian Center for Vaccinology, IWK Health Centre, Halifax, Canada.

Peter McIntyre (P)

National Centre for Immunisation Research and Surveillance and The Children's Hospital Westmead, Sydney, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
The IMPACT and PAEDS investigators are acknowledged at the end of this article.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH